{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=51", "query": { "condition": "Cancer", "page": 51 }, "page_size": 10 }, "pagination": { "page": 51, "page_size": 10, "total_count": 6203, "total_pages": 621, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=52&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=50&page_size=10" }, "source": "local", "last_synced_at": "2026-10-28T02:41:45.298Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03774758", "title": "Biomarkers for Risk Stratification in Lung Cancer", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Nodule Solitary Pulmonary", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Guardant Health ct-DNA LUNAR assay", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 1440, "start_date": "2017-12-17", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-14T23:55:04.324Z", "location_count": 3, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03774758" }, { "nct_id": "NCT00870129", "title": "Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Brain Cancer", "Glioma" ], "interventions": [ { "name": "MRI and advanced MRI sequences", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 135, "start_date": "2009-03", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-15T23:39:37.600Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00870129" }, { "nct_id": "NCT07869836", "title": "BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bladder (Urothelial, Transitional Cell) Cancer", "Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable", "Bladder Ca", "Bladder Cancer", "Bladder Cancer (BC)", "Bladder Cancer Recurrent", "Bladder Cancer Stage IV", "Metastatic Urothelial Cancer", "Urothelial Cancer", "Urothelial Carcinoma Bladder", "Urothelial Carcinoma Recurrent", "Urothelial Carcinoma of the Urinary Bladder" ], "interventions": [ { "name": "Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin)", "type": "DRUG" }, { "name": "T-Bren, Dose level 1", "type": "DRUG" }, { "name": "T-bren, Dose level 2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SystImmune Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 520, "start_date": "2026-09", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-13T22:36:55.433Z", "location_count": 1, "location_summary": "Macon, Georgia", "locations": [ { "city": "Macon", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07869836" }, { "nct_id": "NCT07843940", "title": "A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Small Cell Lung Cancer", "Extensive-stage Small Cell Lung Carcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Obrixtamig", "type": "DRUG" }, { "name": "Pumitamig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2026-10-01", "completion_date": "2030-04-21", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-15T01:26:39.333Z", "location_count": 5, "location_summary": "Miami, Florida • Boston, Massachusetts • East Brunswick, New Jersey + 2 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "East Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07843940" }, { "nct_id": "NCT07769502", "title": "A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma", "Pancreatobiliary Cancers" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "Telisotuzumab Adizutecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 168, "start_date": "2026-08-17", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-14T15:06:20.014Z", "location_count": 1, "location_summary": "Hattiesburg, Mississippi", "locations": [ { "city": "Hattiesburg", "state": "Mississippi" } ], "official_url": "https://clinicaltrials.gov/study/NCT07769502" }, { "nct_id": "NCT07725796", "title": "A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder (Urothelial, Transitional Cell) Cancer", "NMIBC", "Non-Muscle Invasive Bladder Carcinoma", "Non-muscle Invasive Bladder Cancer (NMIBC)", "Urothelial Carcinoma Bladder", "Urothelial Carcinoma Recurrent", "Urothelial Carcinoma in Situ", "Urothelial Carcinoma of the Urinary Bladder" ], "interventions": [ { "name": "UGN-501", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-09-28", "completion_date": "2029-08-02", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-14T19:26:41.517Z", "location_count": 15, "location_summary": "Queen Creek, Arizona • Bakersfield, California • Murrieta, California + 12 more", "locations": [ { "city": "Queen Creek", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Murrieta", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07725796" }, { "nct_id": "NCT07621718", "title": "Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "PDAC", "PDAC - Pancreatic Ductal Adenocarcinoma", "Pancreatic Adenocarcinoma", "Pancreatic Adenocarcinoma Metastatic", "Pancreatic Adenosquamous Carcinoma", "Pancreatic Cancer", "Pancreatic Cancer Metastatic", "Pancreatic Ductal Adenocarcinoma (PDAC)" ], "interventions": [ { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Gemcitabine (GEM)", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Leucovorin (Calcium Folinate)", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Zoldonrasib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revolution Medicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 670, "start_date": "2026-05-22", "completion_date": "2030-04-22", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-13T22:49:56.206Z", "location_count": 18, "location_summary": "Phoenix, Arizona • Tucson, Arizona • New Haven, Connecticut + 14 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07621718" }, { "nct_id": "NCT07578116", "title": "Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic HER2-Positive Breast Carcinoma", "Oligometastatic Breast Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Breast Conservation Treatment", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclin-Dependent Kinase 4 Inhibitor", "type": "DRUG" }, { "name": "Cyclin-Dependent Kinase 6 Inhibitor", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "HER2-targeted Therapy", "type": "DRUG" }, { "name": "Hormone Therapy", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mammography", "type": "PROCEDURE" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Radiation Boost", "type": "RADIATION" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" }, { "name": "Taxane Compound", "type": "DRUG" }, { "name": "Total Mastectomy", "type": "PROCEDURE" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab Deruxtecan", "type": "BIOLOGICAL" }, { "name": "Trastuzumab Emtansine", "type": "BIOLOGICAL" }, { "name": "Ultrasound Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 562, "start_date": "2027-03-09", "completion_date": "2033-05-31", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-13T20:47:40.194Z", "location_count": 59, "location_summary": "Jonesboro, Arkansas • Derby, Connecticut • Fairfield, Connecticut + 45 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Derby", "state": "Connecticut" }, { "city": "Fairfield", "state": "Connecticut" }, { "city": "Greenwich", "state": "Connecticut" }, { "city": "Guilford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT07578116" }, { "nct_id": "NCT07541170", "title": "A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Divarasib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2026-10-06", "completion_date": "2035-03-31", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-28T02:41:45.298Z", "location_count": 6, "location_summary": "Clovis, California • Atlanta, Georgia • Farmington Hills, Michigan + 2 more", "locations": [ { "city": "Clovis", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Farmington Hills", "state": "Michigan" }, { "city": "Reno", "state": "Nevada" }, { "city": "Reno", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT07541170" }, { "nct_id": "NCT07519655", "title": "Phase 1 Study of PF-08046033 in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cutaneous Melanoma", "Esophageal Cancer", "Non-Small-Cell Lung" ], "interventions": [ { "name": "PF-08046033", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2026-04-08", "completion_date": "2029-07-14", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-14T04:29:10.594Z", "location_count": 11, "location_summary": "Denver, Colorado • New Haven, Connecticut • Trumbull, Connecticut + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT07519655" } ] }